Tamoxifen treatment of advanced endometrial carcinoma. A phase II study.
The objective of the present phase II trial was to analyze the efficacy of the antiestrogen tamoxifen in advanced endometrial carcinoma. 32 patients with measurable disease entered the study and were treated with tamoxifen 10 mg 3 times daily. Among 26 patients with evaluable disease remission (partial and complete) was achieved in 8 (30%), no change in 7 (27%) and progressive disease in 11 (42%). Duration of response was significantly longer in 4 patients with complete remission (30.5 + months) compared to patients with partial remission and no change. No correlation was found between response to treatment with tamoxifen and disease free interval but a favourable connection was observed between good response and low grade of anaplasia of the tumor. 9 of the patients had received prior treatment with MPA. No complete cross resistance or cross sensitivity between MPA and tamoxifen was apparent.
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000970:Antineoplastic Agents; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D009365:Neoplasm Regression, Spontaneous; D009367:Neoplasm Staging; D013629:Tamoxifen / Q000627:therapeutic use*; D013997:Time Factors; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000970:Antineoplastic Agents; D013629:Tamoxifen